John Edward LYNCH
Known title: DirectorCIK: 0001865686
Associated companies
Transaction History
| IGC | ▲ Buy | Option Exercise | 9,375 | $0 | 6/1/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 28,125 | $0 | 5/31/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 9,375 | $0 | 6/1/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 28,125 | $0 | 5/31/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused
IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused. IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.